Eli Lilly to buy psychedelic-focused AtaiBeckley for $2.8 billion, aiming for a DMT-based treatment for resistant depression

Eli Lilly said it will acquire AtaiBeckley, a drugmaker focused on psychedelic medicines, in a deal valued at $2.8 billion. The proposed transaction is designed to expand Lilly’s psychiatry portfolio with a product candidate that uses DMT, a naturally occurring psychedelic compound, administered as a nasal spray.

The asset at the center of the deal is being positioned for treatment-resistant depression, a form of major depressive disorder that does not respond adequately to standard therapies. According to the announcement reported in market coverage, the nasal spray has received FDA Breakthrough Therapy Designation, an expedited development status intended to help bring potentially transformative treatments to patients more quickly when early evidence suggests substantial improvement over existing options.

The deal also highlights a broader shift in large pharmaceutical companies toward late-stage or development-stage therapies in neuropsychiatry, including treatments that use novel mechanisms of action. For Lilly, expanding beyond its core lines of chronic-care medicines into additional psychiatric options is one way to broaden the set of growth drivers that can offset the long-term impact of patent expirations and competitive pressures in existing categories.

Details on the timing of the acquisition and the specific structure of the $2.8 billion transaction were not included in the reported market account. The company also did not, in that coverage, provide additional clinical detail such as the size or results of pivotal trials, the planned next regulatory filing, or how the DMT nasal spray compares against existing depression therapies in terms of efficacy and safety.

A key term in the reported rationale is the FDA Breakthrough Therapy Designation. Breakthrough Therapy Designation does not amount to approval, and it does not guarantee an eventual marketing authorization. It generally indicates that regulators believe early clinical data warrant more intensive guidance and closer support from the agency during development, which can affect study design and review timelines.

For investors and competitors, the acquisition may announcement Lilly’s willingness to underwrite riskier, earlier-stage development profiles in exchange for access to differentiated science. AtaiBeckley’s DMT nasal spray also sits within a field that has generated both scientific interest and regulatory scrutiny, given the novelty of psychedelic-inspired therapeutic approaches and the need for robust evidence on treatment outcomes and tolerability.

Still, major uncertainties remain. The market report does not lay out what stage the DMT nasal spray is in across its clinical program, what endpoints were most recently demonstrated, or what manufacturing and commercialization pathway Lilly plans to use if the therapy advances. Lilly also did not specify, in the reported account, any near-term milestones tied to the acquisition or whether it expects to conduct additional studies before seeking approval.

What to watch next is whether Lilly will provide expanded disclosures on the program’s development status, trial results, and planned regulatory steps for the DMT nasal spray. Buyers in this space often face long timelines from early evidence to confirmatory trials, so the next set of clinical and regulatory updates will be important for assessing how quickly the product could move from designation to potential approval, and what financial impact, if any, the acquisition might have on Lilly’s pipeline over the coming years.